Synthesis and evaluation of a 18F-labeled 4-ipomeanol as an imaging agent for CYP4B1 gene prodrug activation therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 8, 2013, Pages 588-597

  Moon, Byung Seok ^a,b   Jang, Su Jin ^c   Kim, Sung Joo ^c   Lee, Tae Sup ^c   Chi, Dae Yoon ^d   Lee, Byung Chul ^a,b   Kang, Joo Hyun ^c   Kim, Sang Eun ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

^d Sogang University   (South Korea)

Author keywords

4 ipomeanol; CYP4B1; fluorine 18; gene prodrug activation therapy

Indexed keywords

4 IPOMEANOL; CYTOCHROME P450 4B1; FLUORINE 18; 4-IPOMEANOL; CYTOCHROME P 450 CYP4B1; CYTOCHROME P-450 CYP4B1; FLUORINE; PRODRUG; RADIOPHARMACEUTICAL AGENT; TERPENE; UNSPECIFIC MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CELL ASSAY; FLUORINATION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GLIOMA; HUMAN; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG STABILITY; ENZYMOLOGY; FISCHER 344 RAT; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; DRUG STABILITY; FLUORINE RADIOISOTOPES; GLIOMA; HUMANS; ISOTOPE LABELING; PRODRUGS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; TERPENES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84884550961     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1408     Document Type: Article

References (22)

1. Bridgewater G, Springer CJ, Knox R, et al. Expression of the bacterial. nitroreductase enzyme in mammal.ian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995;31A:2362.
2. Czerwinski M, McLemore TL, Philpot RM, et al. Metabolic activation of 4-ipomeanol by complementary DNAexpressed human cytochromes P-450: Evidence for speciesspecific metabolism. Cancer Res 1991;51:4636.
3. Boyd MR, Wilson BJ. Isolation and characterization of 4-ipomeanol, a lung-toxic furanoterpenoid produced by sweet potatoes (Ipomoea batatas). J Agric Food Chem 1972;20:428.
4. Boyd MR, Wilson BJ, Harris, TM. Confirmation by chemical. synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nat New Biol 1972;236:158.
5. Boyd MR, Burka LT, Harris TM, et al. Lung-toxic furanoterpenoids produced by sweet potatoes following microbial. infection. Biochim Biophys Acta 1974;337:184.
6. Verschoyle RD, Philpot RM, Wolf CR, et al. CYP4B1 activates 4-ipomeanol in rat lung. Toxicol Appl Pharmacol 1993; 123:193.
7. Al.varez-Diez TM, Zheng J. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem Res Toxicol 2004;17:150.
8. Rowinsky EK, Noe DA, Ettinger DS. Phase I and pharmacological. study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients; hepatotoxicity is dose limiting in humans. Cancer Res 1993;53:1794.
9. Kasturi VJ, Dearing MP, Piscitelli SC. Phase I study of a fiveday dose schedule of 4-ipomeanol in patients with nonsmal.l cell lung cancer. Clin Cancer Res 1998;4:2095.
10. Lakhanpal. S, Donehover RC, Rowinsky EK. Phase II study of 4-ipomeanol, a natural.ly occurring al.kylating furan, in patients with advanced hepatocellular carcinoma. Invest New Drugs 2001;19:69.
11. Smith PB, Tiano HF, Nesnow S, et al. 4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1. Biochem Pharmacol 1995; 50:1567.
12. Mohr L, Rainov NG, Mohr UG, et al.. Rabbit cytochrome P450 4B1: A novel prodrug bioactivation gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther 2000;7:1008.
13. Ravindranath V, Burka LT, Boyd MR. Reactive metabolites from the bioactivation of toxic methylfurans. Science 1984; 224:884.
14. Ravindranath V, Boyd MR. Metabolic activation of 2-methylfuran by rat microsomal. systems. Toxicol Appl Pharmacol 1985;78:370.
15. Kobayashi T, Sugihara J, Harigaya S. Mechanism of metabolic cleavage of a furan ring. Drug Metab Dispos 1987; 15:877.
16. Chen LJ, Hecht SS, Peterson L. Identification of cis-2-butene-1,4-dial. as a microsomal. metabolite of furan. Chem Res Toxicol 1995;8:903.
17. Khojateh-Bakht SC, Chen W, Koenings LL. Metabolism of (R)-( + )-menthofuran by human liver cytochrome P-450s: Evidence for formation of a furan epoxide. Drug Metab Dispos 1999;27:574.
18. Steffens S, Frank S, Fischer U, et al. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications forprodug activating gene therapy. Cancer Gene Ther 2000; 7:806.
19. Rainov NG, Dobberstein K-U, Sena-Estevens M. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoantracene/4-ipomeanol. Hum Gene Ther 1998;9:1261.
20. Jang SJ, Kang JH, Lee TS, et al. Prodrug-activating gene therapy with rabbit cytochrome P450 4B1/4-ipomeanol or 2-aminoanthracene system in glioma cells. Nucl Med Mol Imaging 2010;44:193.
21. Duarte S, Carle G, Faneca H, et al. Suicide gene therapy in cancer: Where do we stand now? Cancer Lett 2012; 324:160.
22. Christian MC, Wittes RE, Leyland-Jones B, et al. Tissue distribution of radioactivity bound coval.ently to tissue protein in rat 24h. J Natl Cancer Inst 1989;81:1133.